Organigram Global (OGI) Competitors

Organigram Global logo
$0.95 -0.01 (-0.94%)
Closing price 04:00 PM Eastern
Extended Trading
$0.97 +0.02 (+1.58%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OGI vs. ACB, CGC, CRON, SNDL, and TLRY

Should you buy Organigram Global stock or one of its competitors? MarketBeat compares Organigram Global with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Organigram Global include Aurora Cannabis (ACB), Canopy Growth (CGC), Cronos Group (CRON), SNDL (SNDL), and Tilray Brands (TLRY). These companies are all part of the "pharmaceutical products" industry.

How does Organigram Global compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and Organigram Global (NASDAQ:OGI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Organigram Global has lower revenue, but higher earnings than Aurora Cannabis. Organigram Global is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$247.82M0.71-$88.13M-$1.56N/A
Organigram Global$185.07M0.72-$17.70M-$0.13N/A

Aurora Cannabis has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Organigram Global has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 34.6% of Organigram Global shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by insiders. Comparatively, 0.1% of Organigram Global shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Aurora Cannabis' average media sentiment score of 0.00 equaled Organigram Global'saverage media sentiment score.

Company Overall Sentiment
Aurora Cannabis Neutral
Organigram Global Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Organigram Global
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Organigram Global has a net margin of -9.22% compared to Aurora Cannabis' net margin of -33.57%. Aurora Cannabis' return on equity of 0.10% beat Organigram Global's return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis-33.57% 0.10% 0.07%
Organigram Global -9.22%-13.41%-9.09%

Summary

Organigram Global beats Aurora Cannabis on 8 of the 13 factors compared between the two stocks.

How does Organigram Global compare to Canopy Growth?

Organigram Global (NASDAQ:OGI) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

Organigram Global has a net margin of -9.22% compared to Canopy Growth's net margin of -75.27%. Organigram Global's return on equity of -13.41% beat Canopy Growth's return on equity.

Company Net Margins Return on Equity Return on Assets
Organigram Global-9.22% -13.41% -9.09%
Canopy Growth -75.27%-26.95%-17.20%

Organigram Global has higher earnings, but lower revenue than Canopy Growth. Organigram Global is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organigram Global$185.07M0.72-$17.70M-$0.13N/A
Canopy Growth$251.01M1.52-$190.29M-$0.59N/A

Organigram Global has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

34.6% of Organigram Global shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 0.1% of Organigram Global shares are owned by insiders. Comparatively, 0.2% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Canopy Growth had 9 more articles in the media than Organigram Global. MarketBeat recorded 9 mentions for Canopy Growth and 0 mentions for Organigram Global. Canopy Growth's average media sentiment score of 0.12 beat Organigram Global's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.

Company Overall Sentiment
Organigram Global Neutral
Canopy Growth Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organigram Global
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Canopy Growth
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17

Summary

Organigram Global beats Canopy Growth on 8 of the 14 factors compared between the two stocks.

How does Organigram Global compare to Cronos Group?

Cronos Group (NASDAQ:CRON) and Organigram Global (NASDAQ:OGI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Cronos Group has a net margin of -1.14% compared to Organigram Global's net margin of -9.22%. Cronos Group's return on equity of -1.26% beat Organigram Global's return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos Group-1.14% -1.26% -1.20%
Organigram Global -9.22%-13.41%-9.09%

Cronos Group has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Organigram Global has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market.

Cronos Group currently has a consensus target price of $2.30, suggesting a potential downside of 14.81%. Given Cronos Group's higher possible upside, equities analysts clearly believe Cronos Group is more favorable than Organigram Global.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cronos Group
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Organigram Global
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 34.6% of Organigram Global shares are owned by institutional investors. 7.8% of Cronos Group shares are owned by insiders. Comparatively, 0.1% of Organigram Global shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cronos Group has higher earnings, but lower revenue than Organigram Global. Organigram Global is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$146.59M6.87-$9.45M$0.01270.00
Organigram Global$185.07M0.72-$17.70M-$0.13N/A

In the previous week, Cronos Group had 3 more articles in the media than Organigram Global. MarketBeat recorded 3 mentions for Cronos Group and 0 mentions for Organigram Global. Cronos Group's average media sentiment score of 0.71 beat Organigram Global's score of 0.00 indicating that Cronos Group is being referred to more favorably in the media.

Company Overall Sentiment
Cronos Group Positive
Organigram Global Neutral

Summary

Cronos Group beats Organigram Global on 11 of the 15 factors compared between the two stocks.

How does Organigram Global compare to SNDL?

SNDL (NASDAQ:SNDL) and Organigram Global (NASDAQ:OGI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

SNDL has higher revenue and earnings than Organigram Global. SNDL is trading at a lower price-to-earnings ratio than Organigram Global, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SNDL$937.39M0.39-$11.29M-$0.03N/A
Organigram Global$185.07M0.72-$17.70M-$0.13N/A

In the previous week, SNDL had 1 more articles in the media than Organigram Global. MarketBeat recorded 1 mentions for SNDL and 0 mentions for Organigram Global. SNDL's average media sentiment score of 0.00 equaled Organigram Global'saverage media sentiment score.

Company Overall Sentiment
SNDL Neutral
Organigram Global Neutral

34.6% of Organigram Global shares are owned by institutional investors. 0.1% of Organigram Global shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

SNDL has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Organigram Global has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market.

SNDL presently has a consensus price target of $5.00, suggesting a potential upside of 249.65%. Given SNDL's higher possible upside, equities analysts plainly believe SNDL is more favorable than Organigram Global.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SNDL
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Organigram Global
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

SNDL has a net margin of -1.19% compared to Organigram Global's net margin of -9.22%. SNDL's return on equity of -1.02% beat Organigram Global's return on equity.

Company Net Margins Return on Equity Return on Assets
SNDL-1.19% -1.02% -0.85%
Organigram Global -9.22%-13.41%-9.09%

Summary

SNDL beats Organigram Global on 8 of the 15 factors compared between the two stocks.

How does Organigram Global compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Organigram Global (NASDAQ:OGI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

9.4% of Tilray Brands shares are owned by institutional investors. Comparatively, 34.6% of Organigram Global shares are owned by institutional investors. 0.8% of Tilray Brands shares are owned by company insiders. Comparatively, 0.1% of Organigram Global shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Tilray Brands has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market. Comparatively, Organigram Global has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

Organigram Global has a net margin of -9.22% compared to Tilray Brands' net margin of -156.51%. Tilray Brands' return on equity of -3.31% beat Organigram Global's return on equity.

Company Net Margins Return on Equity Return on Assets
Tilray Brands-156.51% -3.31% -2.42%
Organigram Global -9.22%-13.41%-9.09%

Organigram Global has lower revenue, but higher earnings than Tilray Brands. Organigram Global is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tilray Brands$821.31M0.65-$2.19B-$13.65N/A
Organigram Global$185.07M0.72-$17.70M-$0.13N/A

Tilray Brands currently has a consensus price target of $11.50, suggesting a potential upside of 149.46%. Given Tilray Brands' higher probable upside, equities research analysts clearly believe Tilray Brands is more favorable than Organigram Global.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tilray Brands
1 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.25
Organigram Global
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Tilray Brands had 21 more articles in the media than Organigram Global. MarketBeat recorded 21 mentions for Tilray Brands and 0 mentions for Organigram Global. Tilray Brands' average media sentiment score of 0.64 beat Organigram Global's score of 0.00 indicating that Tilray Brands is being referred to more favorably in the media.

Company Overall Sentiment
Tilray Brands Positive
Organigram Global Neutral

Summary

Tilray Brands beats Organigram Global on 10 of the 16 factors compared between the two stocks.

Get Organigram Global News Delivered to You Automatically

Sign up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OGI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OGI vs. The Competition

MetricOrganigram GlobalMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$135.14M$8.08B$6.45B$12.39B
Dividend YieldN/A2.60%2.69%5.83%
P/E Ratio-7.3215.2424.9223.97
Price / Sales0.726.99528.81109.59
Price / CashN/A16.8344.8254.51
Price / Book0.513.2110.796.50
Net Income-$17.70M$226.25M$3.56B$336.88M
7 Day Performance-5.84%-3.57%1.67%-0.22%
1 Month Performance-15.09%-3.72%0.43%0.77%
1 Year Performance-25.70%1.93%32.84%31.57%

Organigram Global Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OGI
Organigram Global
0.5361 of 5 stars
$0.95
-0.9%
N/A-25.6%$135.14M$185.07MN/A1,139
ACB
Aurora Cannabis
0.3321 of 5 stars
$3.01
+2.0%
N/A-29.7%$184.63M$247.82MN/A1,130
CGC
Canopy Growth
1.4969 of 5 stars
$0.96
-2.8%
N/A-22.8%$386.22M$225.65MN/A3,150
CRON
Cronos Group
1.5352 of 5 stars
$2.61
-0.8%
$2.30
-11.9%
+42.5%$973.61M$146.59M261.26450
SNDL
SNDL
3.4634 of 5 stars
$1.44
+0.3%
$5.00
+248.4%
+12.0%$369.37M$677.32MN/A2,751

Related Companies and Tools


This page (NASDAQ:OGI) was last updated on 6/23/2026 by MarketBeat.com Staff.
From Our Partners